<DOC>
	<DOCNO>NCT02733822</DOCNO>
	<brief_summary>Naloxone standard treatment response case suspect opiate overdose . Buccal formulation naloxone novel alternative license naloxone injection , remove risk accidental needle-stick , may safer easy administer . Current UK policy allow emergency administration naloxone member general public ( Strang , Kelleher , Best , Mayet , &amp; Manning , 2006 ) , preventative provision naloxone drug user family member ( `` take-home naloxone '' ) possible prescription basis . Thus , buccal naloxone may particularly suitable administration family member provide interim overdose management care await arrival ambulance . The aim study examine bioavailability dose proportionality buccal naloxone compare licensed injection standard ( intravenous , intramuscular ) . The investigator hypothesise buccal naloxone inferior injection reference absorption kinetics , i.e . time elapse till peak concentration ( Tmax; primary outcome ) , peak plasma concentration ( Cmax ) , overall absorption ( AUC ) , bioavailability ( F % ) , duration action ( mean terminal half-life; T1/2 ) . The investigator propose pharmacokinetic pilot investigation within-subjects ( crossover ) design , compare two dos ( 0.8 mg; 1.6 mg ) buccal naloxone hydrochloride solution license intramuscular ( IM; 0.8 mg ) intravenous ( IV; 0.8 mg ) rout injection . The investigator invite four healthy ( i.e. , non-opioid use ) male volunteer ( n=4 , power ) , attend four experimental session counterbalance sequence . Each volunteer receive naloxone hydrochloride dose 0.8 mg IM , 0.8 mg IV , 0.8 mg buccal , 1.6 mg buccal , one dose administer per session . Blood concentration measure select time session establish speed naloxone absorption , time peak concentration , estimate half-life , overall bioavailability . This dose-ranging pilot inform future work provide preliminary data buccal naloxone absorption bloodstream establish feasibility buccal route naloxone delivery .</brief_summary>
	<brief_title>Buccal Versus Injectable Naloxone : Phase I Healthy Volunteer Study</brief_title>
	<detailed_description>Blood sample ( 3 ml ) collect -5 , +1 , 2 , 3 , 4 , 6 , 8 , 10 , 12.5 , 15 , 30 , 45 , 60 , 75 , 90 , 120 , 150 , 180 , 240 , 300 , 360 , 420 , 480 minute .</detailed_description>
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Drug Overdose</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<criteria>1 . Adult male age 18 64 year inclusive 19 29.9 kg/m2 body mass index ( BMI ) . 2 . Subjects healthy determine prestudy medical history physical examination . 3 . Subjects able willing give write informed consent . 4 . Medical history must verify either personal physician medical practitioner appropriate . 1 . Subjects conform inclusion criterion . 2 . Subjects clinical condition ( abnormal liver function , renal cardiac issue ) , opinion personal physician examine medical practitioner , make participation study inappropriate . 3 . Subjects clinically relevant surgical history . 4 . Subjects clinically relevant family history . 5 . Subjects history relevant atopy . 6 . Subjects history drug hypersensitivity relevant naloxone . 7 . Subjects history alcoholism . 8 . Subjects history drug abuse . 9 . Subjects consume 42 unit alcohol week . ( unit = 1 glass wine ( 125 mL ) = 1 measure spirit = ½ pint beer ) 10 . Subjects acute infection ( influenza ) relevant lesion ( oral tract ) time screen admission . Subjects rescreened recover . At rescreening , urine test drug abuse alcohol parameter need repeat . 11 . Subjects use prescription drug within 4 week first dose . 12 . Subjects use counter medication contain codeine opiate within 7 day first dose , unless agree clinically relevant Principal Investigator . Details document source data . 13 . Subjects use investigational drug clinical trial within 3 month receive last dose . 14 . Subjects receive last dose IMP great 3 month ago extend followup 15 . Subjects communicate reliably Investigator . 16 . Subjects unlikely cooperate requirement study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>opiate</keyword>
	<keyword>heroin</keyword>
	<keyword>opioid</keyword>
	<keyword>overdose</keyword>
	<keyword>naloxone</keyword>
</DOC>